- Report
- October 2023
- 70 Pages
Global
From €3368EUR$3,495USD£2,897GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1445EUR$1,500USD£1,243GBP
- Report
- January 2022
- 60 Pages
Global
From €3806EUR$3,950USD£3,274GBP
- Report
- July 2020
- 143 Pages
Global
From €6697EUR$6,950USD£5,761GBP
- Report
- August 2022
- 115 Pages
Global
From €4336EUR$4,500USD£3,730GBP
- Report
- December 2022
- 163 Pages
Global
From €2409EUR$2,500USD£2,072GBP
- Report
- August 2022
Global
From €761EUR$790USD£655GBP
- Report
- August 2022
United States
From €1869EUR$1,940USD£1,608GBP
- Clinical Trials
- January 2020
- 90 Pages
Global
From €2409EUR$2,500USD£2,072GBP
- Drug Pipelines
- October 2020
- 33 Pages
Global
From €3373EUR$3,500USD£2,901GBP
- Report
- July 2023
- 77 Pages
Global
From €3500EUR$3,891USD£3,116GBP
- Report
- May 2022
- 64 Pages
Global
From €1927EUR$2,000USD£1,658GBP
- Report
- April 2023
- 147 Pages
Global
From €5781EUR$5,999USD£4,972GBP
Dravet Syndrome is a rare, severe form of epilepsy that begins in infancy and is characterized by frequent, prolonged seizures. Treatment of Dravet Syndrome typically involves a combination of antiepileptic drugs, dietary therapies, and other therapies. Within the context of Central Nervous System Drugs, the Dravet Syndrome Drug market is a specialized segment of the larger epilepsy drug market. It is composed of drugs that are specifically designed to treat Dravet Syndrome, as well as drugs that are used off-label to treat the condition.
The Dravet Syndrome Drug market is composed of both generic and branded drugs. Some of the companies in the market include GW Pharmaceuticals, Zogenix, Eisai, and UCB. Show Less Read more
